Transplant immunology for non-immunologist

Area of Science:

• Transplantation immunology
• Organ transplant outcomes
• Immunosuppression strategies

Background:

• Solid-organ transplantation is a vital treatment for end-stage organ failure.
• While acute rejection rates are low (<10%) due to advances in immune suppression and human leukocyte antigen (HLA) matching, long-term allograft survival remains suboptimal.
• Chronic allograft injury, partly immune-mediated, poses a significant challenge to long-term transplant success.

Purpose of the Study:

• To review advances in transplantation, focusing on immune-mediated chronic allograft injury.
• To discuss current and emerging immunomodulatory therapies aimed at improving long-term allograft survival.
• To highlight the ongoing challenge of inducing immune tolerance in transplantation.

Main Methods:

• Review of advancements in immune suppression and human leukocyte antigen (HLA) matching techniques.
• Discussion of tissue-typing and crossmatch testing in preventing severe rejection.
• Exploration of novel immunomodulatory therapies targeting T-cell and B-cell immunology, including antibody reduction and removal.

Main Results:

• Significant reduction in acute rejection rates (<10%) achieved through improved HLA matching and immunosuppression.
• Development of therapies that decrease or remove anti-HLA antibodies, enabling ABO-incompatible transplantation and transplantation in sensitized patients.
• Despite improvements, chronic allograft injury persists, necessitating lifelong immunosuppression.

Conclusions:

• Current immunosuppressive strategies have vastly improved short-term transplant outcomes but do not eliminate the need for lifelong medication.
• Chronic allograft injury, driven by complex immune responses including anti-HLA antibodies, remains a major obstacle.
• Induction of immune tolerance, allowing for withdrawal of immunosuppression without rejection, is the ultimate goal but remains a significant challenge in human transplantation.